Lecanemab · Leqembi, Leqembi Iqlik

What is Lecanemab?

Lecanemab is a humanized IgG1 monoclonal antibody that binds aggregated soluble and insoluble forms of amyloid beta, reducing amyloid beta plaques in the brain. It is studied in early Alzheimer's disease and preclinical Alzheimer's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Leqembi, Leqembi Iqlik, BAN-2401

Drug type

Monoclonal antibody

Targets

amyloid beta

Mechanism

Modulator of amyloid beta

Pathways

amyloid beta plaque reduction

Therapy area

Neurology

Developer

Eisai Inc

In trials of

BIIB

FDA status

Approved as Leqembi, Leqembi Iqlik (January 6, 2023), BLA761269 · FDA label

UNII

12PYH0FTU9

✅ FDA-approved uses

• Alzheimer's disease (Leqembi)

From the indications section of the FDA label (version of Jul 21, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early Alzheimer's DiseaseEarly Preclinical Alzheimer's DiseasePreclinical Alzheimer's Disease

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Leqembi (2026-07-21), indications
• ClinicalTrials.gov NCT03887455
• ClinicalTrials.gov NCT03887455

Updated Oct 11, 2026.